Mr. Jacek Antas reports

HELIX BIOPHARMA CORP. ANNOUNCES LATE FILING OF INTERIM FINANCIAL STATEMENTS

Helix BioPharma Corp.'s interim financial statements and accompanying management's discussion and analysis for the six months ended Jan. 31, 2024, may not be filed in time by the filing deadline on March 18, 2024, as required by National Instrument 51-102 -- Continuous Disclosure Obligations. The reason for the anticipated delay is due to a recent change in chief financial officers of the company as announced on Feb. 13, 2024. The company currently expects to file the interim filings by May 18, 2024, and will issue a news release announcing completion of such filing at that time.

The company is applying to the Ontario Securities Commission as its principal regulator and other applicable securities regulators for a volunary management cease trade order (the MCTO). If granted, the MCTO will stay in effect until the interim filings are filed. During the MCTO, the public will continue to be able to trade in the company's common shares. However, the company's chief executive officer and chief financial officer will not be permitted to trade in the common shares.

Until the company files the interim filings, it will comply with the alternative information guidelines set out in National Policy 12-203 -- Management Cease Trade Order. The guidelines, among other things, require the company to issue biweekly default status reports by way of a news release so long as the interim filings have not been filed.

About Helix BioPharma Corp.

Helix BioPharma is a clinical-stage biopharmaceutical company developing unique therapies in the field of immune-oncology for the prevention and treatment of cancer based on the company's proprietary technological platform DOS47. Helix is listed on the Toronto Stock Exchange under the symbol HBP.

We seek Safe Harbor.